Abstract
Feline chronic kidney disease (CKD) is one of the most frequently diagnosed diseases in cats and affects particular older cats. Regenerative therapies are being explored as a potential solution since current treatments largely address symptoms and disease management without targeting underlying tissue repair. The current study preliminary investigates potential adverse events and the feasibility of a systemic application of primed (n = 7) or unprimed (n = 7) equine peripheral blood-derived mesenchymal stem cells (ePB-MSCs) versus placebo control (n = 7). An exploratory, blinded, randomized placebo-controlled study in 21 cats with feline CKD was performed in one veterinary practice with daily owner evaluations and veterinary visits on days 0, 28 ± 3, 56 ± 3, and 84 ± 3 (optional: days 182 ± 7, 365 ± 14, and 547 ± 14). Three serious adverse events were observed throughout the study period: two in the placebo control product (CP) group and one in the primed ePB-MSC group. Generally, it can be concluded that acceptable adverse events were identified in this small cohort after a single intravenous (IV) administration of primed or unprimed ePB-MSCs in cats with CKD. The blood pressure (BP) change from baseline showed no significant treatment effect (p = 0.1543). The lowest (unadjusted) p-value (p = 0.027) was found for the comparison between CP and primed ePB-MSCs at day 56 but failed to be significant as the adjusted comparison-wise significance level equaled p = 0.006. For SDMA (p = 0.9197), quality of life (QOL) (p = 0.9742), and IRIS stage (p = 0.8230), no significant treatment effects were found. In conclusion, the single IV application of ePB-MSCs in cats suffering from CKD showed acceptable adverse events in this small sample size. Based on the current data, there was no evidence that the administration of ePB-MSCs was more effective than the control. Further studies evaluating the efficacy and study limitations of ePB-MSCs in cats suffering from CKD are recommended.
Introduction
CKD is one of the most common diseases in cats and a leading cause of mortality in cats aged 5 years and older. It affects particular older cats, with an increasing prevalence up to 50–80% in cats older than 10–15 years (). CKD is characterized by a tubulointerstitial inflammation and fibrosis, progressively aggravating the renal function in cats, impairing its ability to remove waste products from the blood (). Although several therapeutic interventions are advised, they merely focus on supportive and symptomatic therapy aiming at increasing QOL and delay disease progression. Consequently, there is a high demand for novel and effective treatment options for feline CKD ().
Treatment with mesenchymal stem cells (MSCs) has been proposed as an alternative because MSCs are generally hypothesized to modulate inflammatory and fibrotic pathways. MSCs are plastic-adherent cells which can differentiate into various mesenchymal cell types (for example: osteocytes, chondrocytes, adipocytes, and myocytes) and can be derived from different tissues. Moreover, priming MSCs with pro-inflammatory cytokines has been reported to reduce donor-dependent heterogeneity and enhance their immunomodulatory capacity ().
Recent studies have described the successful isolation of autologous feline MSCs from adipose tissue, fetal fluids and membranes, bone marrow, and peripheral blood and their safe administration. However, the use of autologous MSCs in cats may have limitations because of the development of giant foamy multinucleated cells in later passages (from P5) (). Furthermore, the use of autologous MSCs comprises the need of harvesting tissue from an already immunocompromised patient, which results in lower quality of stem cells. In addition, the MSC quality declines with age, which is not ideal for the treatment of CKD, as this disease mainly occurs in geriatric cats. Finally, as MSCs have to be cultivated for several passages after isolation, autologous MSCs cannot be used to treat an acute onset of inflammation (, ).
Therefore, the use of allogeneic (same species) or xenogeneic (other species) would be an interesting alternative. Using donors allows strict donor selection, ensuring the quality of the stem cells and can be made available immediately. However, the use of allogeneic feline MSCs is limited because of their inadequate proliferation capacity and low isolation capacity compared to human and not humane MSCs (). Equine MSCs have also been shown to be rather promising for the systemic treatment of pets (). Therefore, the xenogeneic use of equine MSCs may offer a very interesting alternative treatment option for CKD, providing an easily available and effective manner to produce MSCs. Furthermore, xenogeneic MSCs offer the advantage of being free of species-specific transferable pathogens when properly in vitro and in vivo tested and manufactured.
For all the aforementioned reasons, the current study aims to evaluate the adverse events and feasibility of ePB-MSCs after a single IV injection for the treatment of feline CKD. The safety hypothesis is that a single IV dose of ePB-MSCs does not cause clinically significant adverse effects, and the effect hypothesis is that cats treated with ePB-MSCs show stabilized or be associated with CKD-related outcomes.
Materials and methods
Study design
The current study was a blinded and placebo-controlled, randomized clinical study evaluating potential adverse events and feasibility of the investigational veterinary product (IVP) ePB-MSCs in the treatment of feline CKD under field conditions in one veterinary practice. The ePB-MSCs were isolated from a young warmblood horse (below 10 years of age) as reported by Spaas et al. () and expanded in culture up to an intermediate cell stock at passage (P) 5 which was frozen at −80 °C for further passaging at a later time. One vial was thawed and cultured to P9 after which they were divided into two groups for another final passage without antibiotics/antimycotics for 3 days with or without priming with pro-inflammatory cytokines. Injected cells are therefore at P10, and both products were characterized in the same way for positive makers and impurity markers as previously described ().
The active substance consisted of pro-inflammatory cytokine primed (IVP1) or unprimed (IVP2) 3×105 cells/mL ePB-MSCs (the same dose and similar injection times up to 3 min./cat: 1 mL) resuspended in 0.9 mL Dulbecco’s Modified Eagle Medium (DMEM) low glucose/mL and cryopreserved with 10% dimethyl sulfoxide (DMSO), sterility tested (including endotoxin levels), and characterized as previously described () (Table 1). No feline-specific infectious-disease screening procedures were performed.
Table 1
| Treatment | Name of product | Application route | Dosage | Day of treatment | Days of observation | Number of animals | |
|---|---|---|---|---|---|---|---|
| T1 | IVP1 group | Primed ePB-MSCs | IV | 1.0 mL | Day 0 | 0, 28 ± 3, 56 ± 3, 84 ± 3, 182 ± 7 (optional) 365 ± 14 (optional) 547 ± 14 (optional) | 7 |
| T2 | IVP2 group | ePB-MSCs | 7 | ||||
| T3 | CP group | Vetivex 9 mg/ml (NaCl) | 7 | ||||
Study design.
IVP, investigational veterinary product; CP, control product.
The cells were not washed before injection, and the dose of 3 × 105 ePB-MSCs was slowly injected and used in the current study based on successful data at this dose with the systemic application of xenogeneic ePB-MSCs in osteoarthritic dogs ().
The study was controlled by a placebo CP group receiving Vetivex 9 mg/mL (Dechra Limited, Staffordshire ST7 1XW, UK), applied at the same volume (1.0 mL) and administration route (IV) as the IVP group (Table 1). Vetivex has no known therapeutic effect on CKD and was therefore considered to be the most appropriate control.
Thawing of the IVP was performed according to the manufacturer’s guidelines (BIVMB, Evergem, Belgium). The IVP was manipulated and injected following sterile technique, in a clean environment. The IVP was administered immediately after thawing to prevent significant cell death. Using appropriate gloves, the vial was taken from the freezer/liquid nitrogen and the cryotube was thawed in the palm of a hand until the content is completely thawed (approximately 5 min). The CP was aspirated at room temperature.
Administration of the IVP or CP was performed by the dispenser by IV injection following usual antiseptic procedure. IV treatment administration was performed in a vein of the front limb, in the cephalic vein at the level of the mid third of the radius, wherever possible or in the jugular vein. After treatment administration, the catheter was flushed with 1 mL saline solution (0.9%) in all groups.
This study was conducted according to European and national regulatory requirements and in compliance with the following documents:
Belgian animal welfare and VMP legislation as applicable to this product and study.
Ethics committee (LA1700607) guidelines as approved in EC_2020_059 and in the deontological derogation DWZ-KF-20-1.15.56.
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes.
Directive 2001/82/EC as amended.
VICH GL9 (Good Clinical Practice, June 2000).
EMA/CVMP/EWP/81976/2010: Guideline on Statistical Principles for Veterinary Clinical Trials, as applicable.
Inclusion and exclusion criteria
Animals were selected on (or before) day 0. Only animals which complied with all of the inclusion criteria and for which none of the exclusion criteria applied were selected for enrollment in the study.
The following inclusion criteria were applied for each animal:
Signed owner informed consent, i.e., owner willing to sign informed consent and able to attend scheduled appointments and closely follow up their cat during the entire study period.
Cats diagnosed with CKD with at least two separate creatinine measurements 2 weeks apart with similar values (stable disease) within 1 month prior to study start (can be old measurements within 1 month prior to study start).
Animals diagnosed preferably with a stage 2 or 3 CKD based on International Renal Interest Society (IRIS) staging (cfr. Table 2).
Non-pregnant, non-lactating, not intended for breeding.
Age ≥12 months.
The cat was in good general health status apart from the target disease, based on initial assessment on day 0 and medical history for the last 2 months.
Cats tested negative for feline immunodeficiency virus (FIV) and feline leukemia virus infection (FeLV).
At least 4 weeks after initiation of a CKD drug treatment (angiotensin-converting enzyme (ACE) inhibitor, telmisartan, or phosphorbinders).
At least 3 weeks after last vaccination.
At least 2 weeks after last steroidal anti-inflammatory drug (SAID) administration or other immunosuppressive treatment.
Cat on the same diet (preferably renal diet) for at least 4 weeks.
Table 2
| Stage | Blood creatinine (μmol/L or mg/dL) | Comments |
|---|---|---|
| At risk | <140 <1.6 | History suggests the animal is at increased risk of developing CKD in the future because of a number of factors (such as exposure to nephrotoxic drugs, breed, high prevalence of infectious disease in the area, or old age). |
| 1 | <140 <1.6 | Non-azotemic. Some other renal abnormality present (such as inadequate urinary concentrating ability without identifiable non-renal cause, abnormal renal palpation or renal imaging findings, proteinuria of renal origin, abnormal renal biopsy results, and increasing blood creatinine concentrations in samples collected serially). |
| 2 | 140–250 1.6–2.8 | Mild renal azotemia (lower end of the range lies within reference ranges for many laboratories, but the insensitivity of creatinine concentration as a screening test means that animals with creatinine values close to the upper reference limit often have excretory failure). Clinical signs usually mild or absent. |
| 3 | 251–440 2.9–5.0 | Moderate renal azotemia. Many extrarenal clinical signs may be present. |
| 4 | >440 >5.0 | Increasing risk of systemic clinical signs and uremic crises. |
IRIS staging of CKD in cats based on SCr concentration.
Cats which met one of the following exclusion criteria were not enrolled in the study:
Age <12 months.
Cats diagnosed at risk or with a CKD IRIS stage 1 or 4.
Pregnant, lactating, intended for breeding.
Any severe medical condition that in the opinion of the investigator would compromise the patient’s safe participation in the study.
Any condition, actual or anticipated, that according to the investigator would restrict or limit the patient’s successful participation for the duration of the study.
Previous participation in a stem cell study.
Animals which were ever treated with MSCs.
Animals that received a CKD drug treatment (ACE inhibitor, telmisartan, or phosphorbinders) within 4 weeks after initiation.
Animals that received vaccinations within 3 weeks before day 0.
Animals that received a treatment with a SAID or other immunosuppressive therapy within 2 weeks before day 0.
Animals that received non-permissible treatments (see Table 3).
Table 3
| Restricted vs allowed products | Product class/name | Time limits for restriction |
|---|---|---|
| Restricted (non-allowed) products and procedures before study start and during study | MSCs | Animals which were ever treated with MSCs should not be enrolled in the study. |
| SAIDs | Within 2 weeks prior to day 0, depending on the drug efficacy period. Longer in case of drug depot applications, dependent on drug efficacy period. During the study. | |
| Vaccinations | Within 3 weeks prior to day 0. During study period. | |
| NSAIDs | Within 7 days prior to day 0. During the study period. | |
| ACE inhibitors, telmisartan, and phosphorbinders | Within 4 weeks prior to day 0. | |
| Allowed products and procedures before study start and during study | Sedatives | Allowed during study period for sedation (e.g., for US assessment, blood, or urine sampling). |
| Opioid derivatives | Allowed during the study period as rescue medication (e.g., methadone, buprenorphine, or equivalent). |
Permissible and non-permissible concomitant treatments.
Blinding and randomization method
The study was blinded by personnel using separate people for clinical examinations (examining veterinarian) and for administration of treatments (dispenser). Therefore, there were two separate teams (examining veterinarian and dispenser) performing the different tasks within the study.
The statistician was responsible to prepare and provide the randomization documentation. A random treatment allocation plan was prepared for the study site and provided separately to the dispenser which was a separate team as the investigator’s team. In addition, the owners, laboratory personnel, ultrasonographers, data managers, and statisticians were blinded. The study followed a randomized block design with the three different treatment groups per block and sequential allocation to ensure an equal distribution of the treatment groups. Randomization is balanced using appropriate block design at the predefined ratio: T1:T2:T3 = 1:1:1.
All cats received an animal ID and were randomly assigned in the three groups as follows: primed ePB-MSCs (FC101, FC105, FC109, FC110, FC115, FC117, and FC120); unprimed ePB-MSCs (FC102, FC104, FC108, FC111, FC113, FC118, and FC119); and CP (FC103, FC106, FC107, FC112, FC114, FC116, and FC121). As it was an exploratory study, there were no primary and secondary efficacy endpoints determined separately a priori.
Study protocol
All owners had to sign an informed consent before the study start, and all animals needed to comply with the aforementioned inclusion and exclusion criteria.
The owner documented a daily observation of their cat throughout the study period with optional completion of owner diary to make sure adverse event reports or disease progression was properly documented. Different veterinary and owner assessments were documented at time points indicated in Table 4. The total duration of the study was 12 weeks (days 0, 28 ± 3, 56 ± 3, to 84 ± 3 per animal). If considered necessary and if possible, the optional long-term follow-up could be done at days 182 ± 7 (6 months), 365 ± 14 (12 months), and 547 ± 14 (18 months) which was recommended (but not mandatory).
Table 4
| Day procedure | Time point of evaluation (days) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 0 prior to treatment | Day 0 treatment | Day 28 ± 3 | Day 56 ± 3 | Day 84 ± 3 | Day 182 ± 5 | Day 365 ± 14 | Day 547 ± 14 | |
| General physical examination | X | X | X | X | (X) | (X) | (X) | |
| Animal treatment | X | |||||||
| Abdominal US | X | |||||||
| Injection site observation | X | X | X | X | (X) | (X) | (X) | |
| Blood sampling | X | X | X | X | (X) | (X) | (X) | |
| Urine sampling | X | X | X | X | (X) | (X) | (X) | |
| IRIS staging | X | X | X | X | (X) | (X) | (X) | |
| QOL score | X | X | X | X | (X) | (X) | (X) | |
Schedule of events. The “X” indicates mandatory visits and the “(X)” as optional visits.
Safety evaluation
Safety was evaluated by general clinical evaluation, injection site evaluation together with assessing the incidence of (serious) adverse events, suspected adverse drug reactions, and/or abnormal general clinical signs. Any type of abnormal signs were also documented.
Complete blood count (CBC) and serum biochemistry (including symmetric dimethylarginine (SDMA), total thyroxine, and electrolytes) were performed. Urine was taken by cystocentesis to perform a complete urinalysis, urine culture, and urine protein–creatinine (UPC) ratio.
A B-mode full abdomen ultrasound (US) examination was performed on a dedicated US machine (Philips, Epic 7), using a microconvex (C8-5) and a linear transducer (L12-5). The criteria for kidney evaluation are kidney shape (normal = bean-shaped), outline (normal = smooth, regular), size (normal = between 30 and 43 mm), echogenicity of cortex and medulla (compared to surrounding tissues and the contralateral kidney), corticomedullary differentiation (clear/sharp), and internal architecture (clearly discernable).
Evaluation of potential clinical effects
Clinical response was evaluated by means of SDMA values, serum creatinine (SCr) values, QOL scores, systolic BP measured using Doppler, and/or time to failure. Failure time (in days) was defined as the period until withdrawal from study due to worsening or no improvement of target disease which required additional treatment not allowed according to the study protocol.
Statistical analysis
The primary aim of the study was to evaluate safety. Therefore, the plan was to allocate cases in a 1:1:1 ratio for CP: unprimed MSCs: primed MSCs including at least four animals and at most eight animals in each treatment group, respectively. The total number of animals used amounted to 21 (seven animals in each treatment group). This total sample size of 21 allows to detect a difference of 0.96 in the CKD value with 80% power using a two-sided t-test at a significance level of 5% (α = 0.05) and assuming the standard deviation equals 0.7.
For safety assessment, the number and percentage of animals with incidence of reported events were presented by the treatment group. Comparison of groups used Fisher’s exact test. Laboratory values being normal at baseline and abnormal post-baseline were summarized with the number and percentage of animals. Hematological and serum chemistry parameters were compared between groups presenting course of means from baseline until day 84 ± 3, and changes from baseline presenting summary statistics groups were compared using the Wilcoxon test. In addition, assessment of deviation from normal ranges was presented and compared between groups using Fisher’s exact test.
For clinical response assessment of SDMA and BP, the normal distribution assumption was tested using the Shapiro–Wilk test. As normality could be assumed, a mixed model was used including time, treatment, and their interaction as categorical fixed-effects factors and animal as random-effects factor. Main effects and interaction were tested by the F-test with the appropriate denominator degrees of freedom obtained through the Satterthwaite’s procedure. Post-hoc pairwise comparisons between the treatments were performed at each time point using the appropriate t-test and adjusting for multiple comparisons by Bonferroni’s technique.
For IRIS staging, QOL, and clinical response, groups were compared using a non-parametric longitudinal analysis. This method was the non-parametric counterpart of the mixed model. Time, treatment, and their interaction were included as categorical fixed-effects factors and cats as stratification factor. These main effects and interaction effect were tested through robust rank-based tests. Furthermore, post-hoc pairwise comparisons between the treatments were performed at each time point using the non-parametric Wilcoxon rank-sum test and adjusting for multiple comparisons by Bonferroni’s technique.
Failure time was compared between the groups using the log-rank test. Cats without failure until the last observation day were used as right censored observations. The proportion of survivors in the treated and control groups were compared using the Fisher exact test to test and the 95% Newcombe–Wilson confidence interval for the difference.
Results
Number of animals included
Seven cats were assigned to each of the treatment groups with a total of 21 animals enrolled in the study. In total, 19 animals reached time point 84 days which were all used for adverse events and clinical response evaluation. The 182-day assessment was achieved in five CP animals, seven primed ePB-MSCs (IVP1), and six unprimed ePB-MSCs (IVP2). Day 365 assessment was available in four CP animals, five primed ePB-MSCs, and five unprimed ePB-MSCs. Day 547 assessment was possible in three animals in each treatment group (Figure 1). The animals were all privately owned cats, and animal details can be found in Table 5.
Figure 1
Table 5
| Baseline parameter | CP (N = 7) | IVP1 (N = 7) | IVP2 (N = 7) | p-value |
|---|---|---|---|---|
| Age (in years) | 0.975 | |||
| N | 7 | 7 | 7 | |
| Mean (SD) | 10.93 (4.59) | 11.71 (4.27) | 11.36 (4.40) | |
| Min-Max | 4.5–17 | 7–17 | 4–17 | |
| Median | 12.00 | 11.00 | 11.0 | |
| Gender | 0.0419 | |||
| Female | 1 | 6 | 5 | |
| Male | 6 | 1 | 2 | |
| Breed | 0.2335 | |||
| Burmilla | 0 | 1 | 0 | |
| British | 1 | 0 | 0 | |
| British Shorthair | 0 | 1 | 0 | |
| European Longhair | 0 | 1 | 0 | |
| European Shorthair | 5 | 2 | 2 | |
| FV | 0 | 2 | 3 | |
| Ragdoll | 1 | 0 | 1 | |
| Siamese | 0 | 0 | 2 | |
| Has the animal any history of recent/recurrent/chronic medical conditions, including surgeries | 0.8541 | |||
| No | 4 | 3 | 5 | |
| Yes | 3 | 4 | 2 | |
| Is the animal currently on therapeutic or prophylactic medication? | 1.0000 | |||
| No | 4 | 3 | 3 | |
| Yes | 3 | 4 | 4 | |
Animal details.
Specific baseline variables were compared between the three groups in Table 5. No significant differences were found except for gender, with an imbalance of male cats occurring more frequently in the placebo group.
Safety evaluation
Incidence of abnormal general clinical signs
The frequency of clinical signs after injection is presented in Table 6 with a comparison between the three treatment groups. The mean presence was shown in order to cope with the missing values. The mean score corresponded to the percentage of assessments with the presence of the clinical sign. None of the general clinical signs showed a significant difference between the treatment groups.
Table 6
| Respvar | Control product | Primed ePB-MSCs | Unprimed ePB-MSCs | p-value | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.25 | 0.50 | 0.75 | 1.00 | 0.00 | 0.25 | 0.50 | 0.75 | 1.00 | 0.00 | 0.25 | 0.50 | 0.75 | 1.00 | ||
| Attitude | 7 | 7 | 7 | 1 | ||||||||||||
| Behavior | 7 | 7 | 7 | 1 | ||||||||||||
| Cardiovascular | 4 | 0 | 3 | 6 | 0 | 1 | 4 | 1 | 2 | 0.5872 | ||||||
| Eyes/ears | 5 | 1 | 1 | 7 | 0 | 0 | 6 | 1 | 0 | 0.6285 | ||||||
| Gastro-intestinal | 7 | 7 | 7 | 1 | ||||||||||||
| Genital tract | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||
| Locomotory system | 7 | 7 | 7 | 1 | ||||||||||||
| Lymphatic system | 7 | 7 | 7 | 1 | ||||||||||||
| Mucous membranes | 7 | 7 | 7 | 1 | ||||||||||||
| Pulse rate | 4 | 3 | 4 | 3 | 6 | 1 | 0.5424 | |||||||||
| Respiratory rate | 3 | 3 | 1 | 0 | 4 | 2 | 0 | 1 | 4 | 2 | 1 | 0 | 0.9607 | |||
| Respiratory tract | 7 | 7 | 7 | 1 | ||||||||||||
| Skin/hair | 5 | 1 | 1 | 0 | 6 | 0 | 0 | 1 | 6 | 1 | 0 | 0 | 0.9129 | |||
| Temperature | 6 | 1 | 0 | 4 | 3 | 0 | 5 | 0 | 1 | 0.7477 | ||||||
| Thyroid | 7 | 0 | 7 | 0 | 6 | 1 | 0.7538 | |||||||||
Overview of number of cats with a particular mean score for the general clinical signs.
Assessment of skin for redness, erosions, ulcerations, and ectopic tissue showed one event in an animal in the primed ePB-MSC group immediately after the injection showing redness. No heat, pain, or swelling at the injection site was observed throughout the rest of the study period in any of the treatment groups.
Incidence of adverse events
Nine animals experienced adverse events. In the CP group (n = 2), animal FC107 experienced idiopathic cystitis, hematuria, and strangury on day 26 followed by death on day 28, and animal FC121 died on day 65 due to falling off the stairs. In the unprimed ePB-MSC group (n = 3), animal FC102 developed hyperthyroidism on day 84 which remained stable during the study period, animal FC104 started the study with hyperthyroidism and died of chronic diarrhea on day 390, and animal FC108 had a temporary poor appetite and was not feeling well on day 84. In the primed ePB-MSC group (n = 4), animal FC101 experienced dyspnea on day 328 and died the day after, animal FC105 had increased liver enzymes on day 182 and dynamic left and right ventricular outflow tract obstruction without clinical relevance, animal FC115 died on day 194 due to renal failure, and animal FC120 had (idiopathic) cystitis on day 58 recovering after treatment.
Out of the nine animals with adverse events as reported above, three were considered serious adverse events throughout the study period. In the primed ePB-MSC group, animal FC115 experienced acute renal failure. Moreover, in the CP group, both animals FC107 and FC121 died during the study.
Hematology and biochemistry
All hematological and serum chemistry variables are summarized in Table 7 where the number of animals having a particular mean presence of values out of the reference range was presented with a comparison between the three treatment groups. No significant differences were observed concerning hematological parameters.
Table 7
| Respvar | Control Product | Primed ePB-MSCs | Unprimed ePB-MSCs | p-value | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.25 | 0.33 | 0.50 | 0.67 | 0.75 | 1.00 | 0.00 | 0.25 | 0.33 | 0.50 | 0.67 | 0.75 | 1.00 | 0.00 | 0.25 | 0.33 | 0.50 | 0.67 | 0.75 | 1.00 | ||
| A/G | 4 | 1 | 1 | 1 | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0.3408 | |||||||||
| ALT | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||||||||
| AST | 6 | 0 | 1 | 6 | 1 | 0 | 6 | 1 | 0 | 0.9867 | ||||||||||||
| Albumin | 5 | 1 | 1 | 6 | 0 | 1 | 7 | 0 | 0 | 0.6474 | ||||||||||||
| Alkaline phosphatase | 7 | 0 | 6 | 1 | 7 | 0 | 0.7538 | |||||||||||||||
| Alpha amylase | 5 | 0 | 0 | 1 | 1 | 5 | 1 | 1 | 0 | 0 | 6 | 0 | 0 | 0 | 1 | 0.9069 | ||||||
| Anisocytosis | 4 | 1 | 1 | 1 | 0 | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 4 | 1 | 1 | 0.2721 | ||||||
| Atypical cells | 7 | 0 | 6 | 1 | 7 | 0 | 0.7538 | |||||||||||||||
| Band_neutroabsolute | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Basophils absolute | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Bilirubin tot | 7 | 7 | 7 | 1 | ||||||||||||||||||
| CK | 6 | 1 | 5 | 2 | 7 | 0 | 0.5385 | |||||||||||||||
| Calcium | 5 | 1 | 0 | 0 | 1 | 2 | 0 | 2 | 2 | 1 | 6 | 0 | 1 | 0 | 0 | 0.2239 | ||||||
| Chloride | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Cholesterol | 6 | 1 | 0 | 7 | 0 | 0 | 6 | 0 | 1 | 0.8441 | ||||||||||||
| Creatinine | 1 | 1 | 2 | 0 | 3 | 1 | 1 | 0 | 3 | 2 | 4 | 0 | 0 | 0 | 3 | 0.7587 | ||||||
| Eosinophils absolute | 2 | 4 | 1 | 3 | 2 | 2 | 3 | 3 | 1 | 0.9459 | ||||||||||||
| Erythrocytes | 3 | 1 | 0 | 3 | 4 | 0 | 1 | 2 | 6 | 1 | 0 | 0 | 0.3023 | |||||||||
| Fructosamine | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||||||||
| GGT | 7 | 0 | 7 | 0 | 6 | 1 | 0.7538 | |||||||||||||||
| GLDH | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Globulin | 5 | 1 | 1 | 7 | 0 | 0 | 7 | 0 | 0 | 0.5255 | ||||||||||||
| Glucose | 6 | 0 | 1 | 2 | 3 | 2 | 4 | 2 | 1 | 0.3326 | ||||||||||||
| A/G | 4 | 1 | 1 | 1 | 7 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0.3408 | |||||||||
| ALT | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||||||||
| AST | 6 | 0 | 1 | 6 | 1 | 0 | 6 | 1 | 0 | 0.9867 | ||||||||||||
| Albumin | 5 | 1 | 1 | 6 | 0 | 1 | 7 | 0 | 0 | 0.6474 | ||||||||||||
| Hemoglobin | 2 | 1 | 1 | 0 | 0 | 3 | 3 | 0 | 1 | 1 | 0 | 2 | 4 | 1 | 1 | 0 | 1 | 0 | 0.5106 | |||
| Inorganic Phosphatase | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||||||||
| Leukocytes | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Lymphocyte absolute | 5 | 2 | 0 | 6 | 0 | 1 | 5 | 2 | 0 | 0.9675 | ||||||||||||
| MCH | 5 | 0 | 1 | 0 | 1 | 5 | 1 | 1 | 0 | 0 | 5 | 0 | 1 | 1 | 0 | 0.9560 | ||||||
| MCHC | 3 | 1 | 1 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 3 | 0 | 0 | 0.9815 | |||
| MCV | 5 | 1 | 1 | 0 | 5 | 0 | 0 | 2 | 4 | 1 | 1 | 1 | 0.8672 | |||||||||
| Magnesium | 6 | 1 | 7 | 0 | 7 | 0 | 0.7538 | |||||||||||||||
| Monocytes absolute | 3 | 1 | 3 | 3 | 3 | 1 | 2 | 4 | 1 | 0.8755 | ||||||||||||
| PCV | 5 | 1 | 0 | 1 | 5 | 0 | 2 | 0 | 6 | 1 | 0 | 0 | 0.8258 | |||||||||
| Polychromasia | 4 | 3 | 0 | 2 | 4 | 1 | 1 | 2 | 4 | 0.1407 | ||||||||||||
| Potassium | 6 | 0 | 1 | 5 | 2 | 0 | 6 | 0 | 1 | 0.9658 | ||||||||||||
| Protein/creatinine | 2 | 1 | 0 | 2 | 2 | 3 | 2 | 1 | 0 | 1 | 2 | 2 | 0 | 3 | 0 | 0.6571 | ||||||
| SDMA | 0 | 1 | 2 | 4 | 1 | 0 | 0 | 6 | 1 | 0 | 1 | 5 | 0.8925 | |||||||||
| Segmented neutrophils absolute_ | 7 | 0 | 0 | 6 | 0 | 1 | 6 | 1 | 0 | 0.8441 | ||||||||||||
| Sodium | 7 | 0 | 6 | 1 | 7 | 0 | 0.7538 | |||||||||||||||
| Spec gravity | 2 | 1 | 4 | 1 | 2 | 4 | 0 | 2 | 5 | 0.7527 | ||||||||||||
| Total T4 | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Thrombocytes | 7 | 0 | 0 | 6 | 0 | 1 | 6 | 1 | 0 | 0.8441 | ||||||||||||
| Total protein | 5 | 2 | 0 | 6 | 0 | 1 | 7 | 0 | 0 | 0.7057 | ||||||||||||
| Triglycerides | 7 | 7 | 7 | 1 | ||||||||||||||||||
| Urea BUN | 0 | 0 | 1 | 6 | 2 | 1 | 0 | 4 | 2 | 1 | 1 | 3 | 0.3373 | |||||||||
Number of animals having a particular mean presence of values outside the reference range for blood and biochemistry parameters.
The mean presence was shown in order to cope with the missing values. The mean score corresponds to the percentage of assessments out of the reference interval.
Clinical response evaluation
BP
The BP response variable was first tested for the normal distribution assumption which was valid according to the Shapiro–Wilk test for BP change from baseline both with last observation carried forward (LOCF) (p = 0.20) and without LOCF (p = 0.32). The individual observations together with the mean curves were given separately for each of the three treatments in Figure 2. For BP change from baseline, the overall analysis with LOCF showed no significant effects for treatment (p = 0.1543), time (p = 0.3506), or the interaction between the two factors (p = 0.3018). The lowest (unadjusted) p-value (p = 0.027) was found for the comparison between CP and primed ePB-MSCs at day 56 but failed to be significant as the adjusted comparison-wise significance level equals p = 0.006. On day 84, BP improvement was seen in 4/5 (CP), 5/7 (primed ePB-MSCs), and 4/7 (unprimed ePB-MSCs) cats. On day 182, BP improvement was seen in 2/5 (CP), 5/7 (primed ePB-MSCs), and 4/6 (unprimed ePB-MSCs) cats. On day 365, BP improvement was seen in 2/4 (CP), 3/5 (primed ePB-MSCs), and 3/5 (unprimed ePB-MSCs) cats. On day 547, BP improvement was seen in 1/3 (CP), 2/3 (primed ePB-MSCs), and 3/3 (unprimed ePB-MSCs) cats. Descriptive statistics of the BP over time can be found in Table 8. The individual data per cat can be found in the Supplementary Table S1.
Figure 2
Table 8
| Parameters | Time after treatment | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 28 ± 3 | 56 ± 3 | 84 ± 3 | Mean | |||||||||||
| CP | IVP1 | IVP2 | CP | IVP | IVP2 | CP | IVP1 | IVP2 | CP | IVP1 | IVP2 | CP | IVP1 | IVP2 | |
| BP | |||||||||||||||
| Mean | 162 | 190 | 171 | 151 | 142 | 151 | 159 | 137 | 140 | 152 | 147 | 154 | 156 | 154 | 154 |
| St. error | 8.9 | 8.9 | 8.9 | 8.9 | 8.9 | 8.9 | 9.6 | 8.9 | 8.9 | 10.5 | 8.9 | 8.9 | 5.5 | 5.2 | 5.2 |
| 95% CILo | 144 | 172 | 153 | 134 | 124 | 134 | 140 | 119 | 122 | 131 | 129 | 136 | 145 | 143 | 143 |
| 95% CIUp | 180 | 208 | 189 | 169 | 160 | 169 | 179 | 155 | 158 | 173 | 165 | 172 | 168 | 165 | 165 |
| SDMA | |||||||||||||||
| Mean | 20 | 19 | 19 | 22 | 20 | 19 | 19 | 18 | 20 | 20 | 22 | 21 | 20 | 20 | 20 |
| St. error | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.6 | 2.4 | 2.4 | 2.7 | 2.4 | 2.4 | 2.0 | 1.9 | 1.9 |
| 95% CILo | 15 | 14 | 14 | 18 | 15 | 15 | 14 | 14 | 15 | 15 | 17 | 16 | 16 | 16 | 16 |
| 95% CIUp | 25 | 24 | 24 | 27 | 25 | 24 | 24 | 23 | 25 | 25 | 27 | 26 | 25 | 24 | 24 |
| QOL | |||||||||||||||
| Median | −4 | −4 | −2 | 5 | −2 | −1 | 2 | −3 | −4 | 4 | −2 | 1 | 0.5 | −2.5 | −1.5 |
| IQR | 16 | 27 | 26 | 27 | 24 | 6 | 17 | 33 | 10 | 20 | 30 | 16 | 20.3 | 25.5 | 13.3 |
| Min | −14 | −33 | −25 | −25 | −6 | −8 | −12 | −10 | −55 | −12 | −16 | −7 | −15 | −7 | −16 |
| Max | 5 | 21 | 36 | 23 | 29 | 41 | 23 | 29 | 41 | 23 | 35 | 49 | 17.8 | 26.3 | 41.8 |
| IRIS stage | |||||||||||||||
| Median | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2.3 | 2 | 2 |
| IQR | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 2 | 1 | 0.3 | 1.3 |
| Min | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 2 | 1.5 | 1.3 |
| Max | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 3 | 3 | 3 | 3 | 3.3 | 2.8 | 3 |
Descriptive statistics for the major assessment outcomes.
SDMA and creatinine serum concentrations
The SDMA response variable was first tested for the normal distribution assumption which was valid according to the Shapiro–Wilk test for SDMA change from baseline both with LOCF (p = 0.32) and without LOCF (p = 0.46). The individual observations together with the mean curves were given separately for each of the three treatments in Figure 3. For SDMA change from baseline, the overall analysis with LOCF showed no significant effects for treatment (p = 0.9197), time (p = 0.0867), or the interaction between the two factors (p = 0.8134). On day 84, SDMA improvement was seen in 2/5 (CP), 2/7 (primed ePB-MSCs), and 2/7 (unprimed ePB-MSCs) cats and creatinine in 2/5, 3/7, and 3/7 cats, respectively. On day 182, SDMA improvement was seen in 3/5 (CP), 2/7 (primed ePB-MSCs), and 3/6 (unprimed ePB-MSCs) cats and creatinine in 2/5, 4/7, and 3/6 cats, respectively. On day 365, SDMA improvement was seen in 2/4 (CP), 3/5 (primed ePB-MSCs), and 4/5 (unprimed ePB-MSCs) cats and creatinine in 1/4, 3/5, and 2/5 cats, respectively. On day 547, SDMA improvement was seen in 1/3 (CP), 0/3 (primed ePB-MSCs), and 1/3 (unprimed ePB-MSCs) cats and creatinine in 1/3, 3/3, and 3/3 cats, respectively. Descriptive statistics of the SDMA over time can be found in Table 8. The individual data per cat can be found in the Supplementary Table S1.
Figure 3
QOL
The QOL response variable was first tested for the normal distribution assumption which did not hold according to the Shapiro–Wilk test for QOL change from baseline, neither with LOCF (p < 0.001) nor without LOCF (p < 0.001). The individual observations together with the mean curves were given separately for each of the three treatments in Figure 4. For QOL change from baseline, the overall analysis with LOCF showed no significant effects for treatment (p = 0.9742), time (p = 0.2144), or the interaction between the two factors (p = 0.4863). LOCF may overestimate a possible improved response in this progressive disease because the different evaluated parameters would be expected to deteriorate over time. As there was no LOCF improvement noted, it can be concluded this limitation is therefore excluded as well.
Figure 4
On day 84, QOL improvement was seen in 4/5 (CP), 5/7 (primed ePB-MSCs), and 5/7 (unprimed ePB-MSCs) cats. On day 182, QOL improvement was seen in 4/5 (CP), 5/7 (primed ePB-MSCs), and 5/6 (unprimed ePB-MSCs) cats. On day 365, QOL improvement was seen in 4/4 (CP), 3/5 (primed ePB-MSCs), and 4/5 (unprimed ePB-MSCs) cats. On day 547, QOL improvement was seen in 3/3 (CP), 2/3 (primed ePB-MSCs), and 1/3 (unprimed ePB-MSCs) cats. Descriptive statistics of the QOL over time can be found in Table 8. The individual data per cat can be found in the Supplementary Table S1.
IRIS stage
The IRIS response variable was first tested for the normal distribution assumption which did not hold according to the Shapiro–Wilk test for IRIS change from baseline, neither with LOCF (p = 0.0014) nor without LOCF (p = 0.008). The individual observations were plotted by subject in Figure 5 because the subject plots were overlapping too much due to the discrete nature of the response variable. The mean curves were given separately as well for each of the three treatments in Figure 6. For IRIS change from baseline, the overall analysis with LOCF showed no significant effects for treatment (p = 0.8230), time (p = 0.7113), or the interaction between the two factors (p = 0.2340). On day 84, IRIS stage improvement was seen in 1/5 (CP), 1/7 (primed ePB-MSCs), and 2/7 (unprimed ePB-MSCs) cats. On day 182, IRIS stage improvement was seen in 1/5 (CP), 1/7 (primed ePB-MSCs), and 2/6 (unprimed ePB-MSCs) cats. On day 365, IRIS stage improvement was seen in 0/4 (CP), 1/5 (primed ePB-MSCs), and 1/5 (unprimed ePB-MSCs) cats. On day 547, IRIS stage improvement was seen in 1/3 (CP), 1/3 (primed ePB-MSCs), and 3/3 (unprimed ePB-MSCs) cats. Descriptive statistics of the IRIS stage over time can be found in Table 8. The individual data per cat can be found in the Supplementary Table S1.
Figure 5
Figure 6
Failure time and body weight
In the placebo groups, two animals died out of seven animals and could thus not proceed in the trial. On the other hand, all of the 14 treated cats continued until the end of the trial. The difference in failure proportion between the control and the treatment equals 0.2857 (95% CI: [−0.011; 0.641]) throughout the entire study period. According to the log-rank test, there was no difference with control (p = 0.100). It needs to be mentioned that the CI is broad which make it difficult to interpret survival/failure outcomes.
On day 84, body weight improvement was seen in 3/5 (CP), 5/7 (primed ePB-MSCs), and 1/7 (unprimed ePB-MSCs) cats. On day 182, body weight improvement was seen in 2/5 (CP), 2/7 (primed ePB-MSCs), and 2/6 (unprimed ePB-MSCs) cats. On day 365, body weight improvement was seen in 1/4 (CP), 2/5 (primed ePB-MSCs), and 2/5 (unprimed ePB-MSCs) cats. On day 547, body weight improvement was seen in 1/3 (CP), 1/3 (primed ePB-MSCs), and 0/3 (unprimed ePB-MSCs) cats. The individual data per cat can be found in the Supplementary Table S1.
Discussion
In the current study, 14 cats were treated intravenously with ePB-MSCs and seven cats received an IV injection with the CP. All study participants were monitored for adverse events. Different adverse events were observed in nine animals, of which 2/3 serious adverse events in the CP group and 1/3 in the primed ePB-MSC group and these were all considered unrelated to the ePB-MSC groups. No events related to the injection site, but a temporary redness in the primed ePB-MSC group was observed in one cat. As there was no heat, pain, or swelling at the injection site, this is not considered related to the active substance. For most general clinical sign variables, few events were found in all groups and none were deemed related to the product by the veterinarian. For the CBC and serum chemistry variables, the distribution of observations out of limits was similar in the three treatment groups. It can be concluded that acceptable adverse events were identified in this small cohort after a single IV administration of primed or unprimed ePB-MSCs in cats with CKD. This is in line with safety data from other studies intravenously injecting allogeneic (, ) or xenogeneic () MSCs in cats.
However, it cannot be concluded that there is evidence that the IV application of ePB-MSCs (primed or unprimed) performed better than placebo for any of the five studied response variables, i.e., BP, SDMA, CKD score, QOL score, and failure. The BP results, however, had greater reduction observed in the primed ePB-MSCs group compared to placebo suggesting the hypothesis that BP may serve as a promising outcome measure in follow-up clinical trials. Therefore, it cannot be excluded that a clinical effect can be demonstrated when increasing the sample size and dose to cope with the variance that is somewhat larger than expected. Furthermore, it needs to be mentioned that a single dose of only 3×105 ePB-MSCs was used in the current study based on successful data with the systemic application of xenogeneic ePB-MSCs in osteoarthritic dogs (). However, this could have been too low for CKD in cats and our data support the hypothesis that repeated dosing may have been needed to demonstrate a significant clinical effect. Nevertheless, a dose-related xeno-antibody response was reported in dogs repeatedly intravenously injected with ePB-MSCs resulting in reduced clinical efficacy. Our data suggest the hypothesis that dose–response data and further immunological research in cats need to provide more clarity on the matter.
The absence of significant clinical improvement is in agreement with the study from Quimby et al. () in six cats receiving three doses of 2×106 allogeneic MSC/kg at 2, 4, and 6 weeks where no significant change in SCr, blood urea nitrogen (BUN), potassium, phosphorus (P), glomerular filtration rate (GFR) by nuclear scintigraphy, UPC, or hematocrit was seen compared with placebo-treated cats. These findings are in contrast with the case study from Song et al. () reporting SCr, BUN, and P concentrations reducing below baseline values and reducing IRIS CKD from Stage 4 to Stage 2. Although the cat’s physical condition improved, as shown by an increase in body weight, an improved Body Condition Score (BCS), and the normalization of mucous membrane color, in the study of Song et al. () had only one case without a control group or blinding for treatment.
Parameters of renal function and clinical health (weight, creatinine, BUN, proteinuria, BP, and hematocrit) have been previously shown to improve after MSC therapy in different in vitro and rat kidney models (). When looking at the clinical data in the most recent placebo-controlled studies in larger animal species, such as cats, using 0.3 million ePB-MSCs (current study), 2 or 4 million/infusion (), or 2 million adipose tissue-derived MSCs/kg (), this has not been significantly reproduced on a larger scale so far.
This diverges from a recent systematic review, meta-analysis from Dos Santos et al. () demonstrating overall improved clinical results after MSC treatment of CKD dogs and cats. Moreover, the mean creatinine was lower among animals treated intravenously and intrarenally and a dose of 5 million MSCs had the highest mean difference between the treated and control groups. Indeed, when comparing the 3×105 dose to the data from Dos Santos et al. (), where 4 × 106 MSCs and 5 × 106 MSCs were associated with significant reductions in CKD parameters, the application of 1 × 106 MSCs showed no significant differences compared to the control group. Also conclusions were less definitive due to the high heterogeneity among studies made and within animals. The study of Quimby et al. () also showed no clinical benefit at 2 or 4 million doses of adipose tissue-derived MSCs confirming that the systemically 3×105 dose for the current application in cats might have been too low in the current study to be conclusive.
Further prospective, adequately powered, randomized, placebo-controlled, clinically relevant, dose–response studies including low dose (0.3 × 106 MSCs), medium dose (1–3 × 106 MSCs), and high dose (5 × 106 MSCs) using mixed models to test dose main effect and dose x time interaction and addressing repeated dosing should provide more scientific insights in the matter. This feasibility clinical study used a lower dose, single administration, and a study population at various stages of CKD. Our data suggest that a larger sized study with tighter variability in the study population and assessment of dosing will be needed to tease out potential clinical effects.
Considering priming ePB-MSCs, the current study size was insufficient to show benefit in comparison with unprimed ePB-MSCs compared to placebo control. Acceptable adverse events were identified in this small cohort after a single IV administration; however, the clinical response hypothesis did not show stabilization of CKD-related outcomes and will need future studies to evaluate the potential effectiveness of ePB-MSCs.
Conclusion
In conclusion, the single IV application of unprimed and primed ePB-MSCs in cats suffering from CKD showed acceptable adverse events in this small sample size. The current feasibility study did not show that the IV application of ePB-MSCs was more effective than control. Further studies on a larger scale evaluating the efficacy of higher and repeated doses of ePB-MSCs in cats suffering from CKD are recommended.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal studies were approved by Ethics committee (LA1700607) approval number EC_2020_059 and deontological derogation DWZ-KF-20-1.15.56. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.
Author contributions
NB: Investigation, Writing – original draft. CB: Investigation, Writing – review & editing. SB: Validation, Writing – review & editing. ED: Investigation, Writing – review & editing. LT: Investigation, Writing – review & editing. GP: Investigation, Methodology, Writing – review & editing. LM: Investigation, Writing – review & editing. EB: Investigation, Writing – review & editing. LD: Formal analysis, Investigation, Methodology, Writing – review & editing. JiS: Conceptualization, Writing – review & editing. SV: Investigation, Writing – review & editing. SD: Conceptualization, Writing – review & editing. JaS: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study received funding from Boehringer Ingelheim Veterinary Medicine Belgium NV. The funder had the following involvement with the study: study design, data collection and analysis, decision to publish, and preparation of the manuscript.
Conflict of interest
CB, SB, ED, GP, LT and JaS were all employed by Boehringer Ingelheim or an affiliated company at the time the study was conducted. JaS is now employed by INTIBIO and shareholder of INTIBIO and an inventor of pending patents covering the application in CKD owned by BIVMB (EP21184504.5; EP2022068549).
The author JaS declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2026.1857026/full#supplementary-material
References
1.
SparkesAHCaneySChalhoubSElliottJFinchNGajanayakeIet al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. J Feline Med Surg. (2016) 18:219–39. doi: 10.1177/1098612x16631234,
2.
BrownCAElliottJSchmiedtCWBrownSA. Chronic kidney disease in aged cats: clinical features, morphology, and proposed pathogeneses. Vet Pathol. (2016) 53:309–26. doi: 10.1177/0300985815622975,
3.
RoudebushPPolzinDJRossSJTowellTLAdamsLGDru ForresterS. Therapies for feline chronic kidney disease. What is the evidence?J Feline Med Surg. (2009) 11:195–210. doi: 10.1016/j.jfms.2009.01.004,
4.
ValenciaJYanezRMMuntionSFernandez-GarciaMMartin-RufinoJDZapataAGet al. Improving the therapeutic profile of MSCs: cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity. Front Immunol. (2025) 16:1473788. doi: 10.3389/fimmu.2025.1473788
5.
ArziBKolAMurphyBWalkerNJWoodJAClarkKet al. Feline foamy virus adversely affects feline mesenchymal stem cell culture and expansion: implications for animal model development. Stem Cells Dev. (2015) 24:814–23. doi: 10.1089/scd.2014.0317,
6.
QuimbyJMBorjessonDL. Mesenchymal stem cell therapy in cats: current knowledge and future potential. J Feline Med Surg. (2018) 20:208–16. doi: 10.1177/1098612x18758590,
7.
ZajicLBWebbTLWebbPCoyJWDowSWQuimbyJM. Comparison of proliferative and immunomodulatory potential of adipose-derived mesenchymal stem cells from young and geriatric cats. J Feline Med Surg. (2017) 19:1096–102. doi: 10.1177/1098612x16680703,
8.
ClarkKCFierroFAKoEMWalkerNJArziBTepperCGet al. Human and feline adipose-derived mesenchymal stem cells have comparable phenotype, immunomodulatory functions, and transcriptome. Stem Cell Res Ther. (2017) 8:69. doi: 10.1186/s13287-017-0528-z,
9.
BeertsCBroeckxSYDepuydtETackLVan HeckeLChiersKet al. Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing. Arthritis Res Ther. (2023) 25:190. doi: 10.1186/s13075-023-03168-7,
10.
SpaasJHDe SchauwerCCornilliePMeyerEVan SoomAvan de WalleGR. Culture and characterisation of equine peripheral blood mesenchymal stromal cells. Vet J. (2013) 195:107–13. doi: 10.1016/j.tvjl.2012.05.006
11.
QuimbyJMWebbTLRandallEMarolfAValdes-MartinezADowSW. Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats. J Feline Med Surg. (2016) 18:165–71. doi: 10.1177/1098612x15576980,
12.
SongYLiuYYuYWangYMuYWangSet al. Case report: allogeneic adipose-derived mesenchymal stem cells for severe feline chronic kidney disease. Front Vet Sci. (2025) 12:1632324. doi: 10.3389/fvets.2025.1632324,
13.
DebosschereYDepuydtEPauwelynGBeertsCVan HeckeLVerhaertLet al. Safety and immunomodulatory properties of equine peripheral blood-derived mesenchymal stem cells in healthy cats. Vet Immunol Immunopathol. (2020) 227:110083. doi: 10.1016/j.vetimm.2020.110083,
14.
CavaglieriRCMartiniDSogayarMCNoronhaIL. Mesenchymal stem cells delivered at the subcapsule of the kidney ameliorate renal disease in the rat remnant kidney model. Transplant Proc. (2009) 41:947–51. doi: 10.1016/j.transproceed.2009.01.072,
15.
LeeSRLeeSHMoonJYParkJYLeeDLimSJet al. Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail. (2010) 32:840–8. doi: 10.3109/0886022x.2010.494803,
16.
NinichukVGrossOSegererSHoffmannRRadomskaEBuchstallerAet al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. (2006) 70:121–9. doi: 10.1038/sj.ki.5001521
17.
SemedoPCorrea-CostaMAntonio CenedezeMMaria Avancini Costa MalheirosDAntonia Dos ReisMShimizuMHet al. Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells. (2009) 27:3063–73. doi: 10.1002/stem.214
18.
VillanuevaSCarrenoJESalazarLVergaraCStrodthoffRFajreFet al. Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure. Clin Sci (Lond). (2013) 125:199–210. doi: 10.1042/cs20120644
19.
QuimbyJMWebbTLHabenichtLMDowSW. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther. (2013) 4:48. doi: 10.1186/scrt198,
20.
Dos SantosLGFerreiraPIKrauseA. Mesenchymal stem cell transplantation: systematic review, meta-analysis and clinical applications for acute kidney injury and chronic kidney disease in dogs and cats. Res Vet Sci. (2024) 175:105313. doi: 10.1016/j.rvsc.2024.105313,
Summary
Keywords
cell therapy, chronic kidney disease, feline, mesenchymal stem cells, xenogeneic
Citation
de Bouvre N, Beerts C, Broeckx SY, Depuydt E, Tack L, Pauwelyn G, Van Mulders L, Vanden Broecke E, Duchateau L, Saunders J, Vandenabeele S, Daminet S and Spaas JH (2026) A randomized, prospective, placebo-controlled feasibility study of systemic administration of equine peripheral blood-derived mesenchymal stem cells in feline chronic kidney disease. Front. Vet. Sci. 13:1857026. doi: 10.3389/fvets.2026.1857026
Received
15 April 2026
Revised
08 October 2026
Accepted
09 October 2026
Published
04 November 2026
Volume
13 - 2026
Edited by
Alicia L. Bertone, The Ohio State University, United States
Reviewed by
Ganesh Lahane, University of Miami, United States
Chenwen Huang, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, China
Othman Azalea-Hani, Putra Malaysia University, Malaysia
Amar Pal, International Institute of Veterinary Education and Research, India
Updates
Copyright
© 2026 de Bouvre, Beerts, Broeckx, Depuydt, Tack, Pauwelyn, Van Mulders, Vanden Broecke, Duchateau, Saunders, Vandenabeele, Daminet and Spaas.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jan H. Spaas, jan.spaas@ugent.be
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.